Targeting
Cellular
Senescence.
A pioneering biotechnology platform engineered to act on the fundamental mechanisms of tissue aging. By reprogramming cellular pathways, ANIDRACTIV® induces deep molecular regeneration and restores structural integrity.
For decades, cellular senescence has been trapped between two extremes: superficial topicals or systemic pharmacology.
Tissue longevity and repair do not need the systemic risks of synthetic pharmacology. They require precision biophysical regulation that works in harmony with human cellular biology.
While pharmaceutical senolytics struggle with systemic toxicity and conventional topicals remain inert on the skin surface, ANIDRACTIV® establishes a new standard: targeted management of cellular senescence with zero systemic drug burden and validated tissue regeneration.
The Hayflick Limit
Hayflick and Moorhead demonstrate that human fibroblasts stop dividing after a finite number of replications. Senescence is identified as an intrinsic cellular state — but no therapeutic route exists.
— Milestones summarised from peer-reviewed literature on cellular senescence.
A new frontier in biophysical regeneration,
countering cellular senescence to restore tissue integrity.
Piemmeggi is an advanced biotechnology company dedicated to the discovery and development of innovative molecular complexes to counter cellular senescence. The primary focus, driven by the proprietary ANIDRACTIV® platform, is deep tissue regeneration and skin longevity.
Our goal is to address severe skin aging and loss of viscoelasticity, and to translate the platform into regenerative indications with high unmet clinical need — detailed in the development pipeline below.
- Tissue reprogrammingReprogramming cellular pathways for deep molecular regeneration.
- Anti-senescenceTargeting the core mechanisms of cellular senescence in skin.
- Scientific rigorFrom in silico computational chemistry to in vivo clinical evidence.
- Structural integrityRestoring tissue viscoelasticity and structural integrity.
A collective of experts in molecular sciences and venture capital.
Founded on Paolo Piazzetta's vision in computational chemistry, Piemmeggi unites molecular scientists and venture builders.
We operate with institutional governance, scientific rigor and strict compliance with the European MDR framework.
From computational chemistry
to clinical evidence.
The ANIDRACTIV® platform translates rigorous research models — from the in silico level to in vivo — into real and safe solutions for tissue reprogramming and skin longevity.
| Program | Asset | Indication | TRL | Status | Reference |
|---|---|---|---|---|---|
| AND-01 | ANIDRACTIV® — Core Platform | Tissue reprogramming · Skin longevity | TRL9 | EU MD Registration | Completed |
| AND-02 | Severe Skin Aging Program | Loss of viscoelasticity | TRL8 | Real-Life Pre-Market Trial | In vivo evidence — ongoing |
| AND-03 | Scars & Stretch Marks | Scars, stretch marks, post-acne | TRL8 | Pre-Clinical | In silico/vitro/vivo |
| AND-04 | AI driven clinical diagnosis | SaMD | TRL 5 | IN PROGRESS | Model Validation |
Regenerative Medicine Development Pipeline
ANIDRACTIV® is being advanced across selected cutaneous indications with a structured preclinical and regulatory development framework.
| Therapeutic Area | Biological Target | Mechanism of Action | Stage | TRL | Evidence |
|---|---|---|---|---|---|
| Psoriasis | Senescent keratinocyte pathways / IL-17/IL-23 signalling | Modulates senescent cell signalling and reduces cutaneous inflammation. | Preclinical Development | TRL5 | in silico / in vitro |
| Dermatitis | Epidermal barrier integrity / chronic inflammation | Restores barrier function and reduces inflammatory mediators. | Preclinical Development | TRL5 | in silico / in vitro |
| Cutaneous Ulcers | Tissue remodelling / microvascular support | Promotes extracellular matrix reorganisation and angiogenic support. | Discovery Phase | TRL5 | in silico |
| Burns | Re-epithelialisation / fibrotic scarring | Accelerates keratinocyte migration and limits myofibroblast activation. | Discovery Phase | TRL5 | in silico |
An elite network of scientific and industrial partners.
Join the next chapter of biophysical tissue regeneration.
SMAU Milano · 3–4 November 2026 | STAND D11
PIEMMEGGI presented the ANIDRACTIV® platform to investors, clinical partners and industry stakeholders.
For investors & venture capital
Executive summary, IP portfolio, EU MDR regulatory roadmap and industrial scale-up plan for the ANIDRACTIV® platform.
For clinical & industrial partners
Co-development, licensing and clinical studies on ulcers, burns, psoriasis and dermatitis, plus SaMD collaborations.
For scientific dialogue, partnership or due diligence.
Reach our R&D, regulatory and business development team. We respond to qualified inquiries within five business days.